Skip to content

Glaukos GKOS Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Boston Scientific logo
Boston ScientificBSX
$2.51B+6.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's accrued liabilities, current?
Glaukos (GKOS) reported accrued liabilities, current of $70.26M in Q1 2026.
How has Glaukos's accrued liabilities, current changed year-over-year?
Glaukos's accrued liabilities, current increased by 33.3% year-over-year, from $52.7M to $70.26M.
What is the long-term trend for Glaukos's accrued liabilities, current?
Over 5 years (2020 to 2025), Glaukos's accrued liabilities, current has grown at a 11.1% compound annual growth rate (CAGR), from $45.33M to $76.65M.